Skip to main content

Drug Interactions between lenacapavir and rufinamide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

rufinamide lenacapavir

Applies to: rufinamide and lenacapavir

MONITOR: Coadministration with drugs that are inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of lenacapavir which may lead to diminished virologic response. The proposed mechanism is increased clearance due to induction of CYP450 3A4, which is partly responsible for the metabolism of lenacapavir. In pharmacokinetic studies conducted in fasted subjects without HIV, coadministration of a single oral dose of lenacapavir 300 mg with the potent CYP450 3A4 inducer rifampin 600 mg once daily decreased the systemic exposure (AUC) and peak plasma concentration (Cmax) of lenacapavir by approximately 84% and 55%, respectively. In the same studies, coadministration of a single oral dose of lenacapavir 300 mg with the moderate CYP450 3A4 inducer efavirenz 600 mg once daily decreased the AUC and Cmax of lenacapavir by approximately 56% and 36%, respectively. No data are available for other, less potent CYP450 3A4 inducers.

MANAGEMENT: The potential for reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels should be considered during coadministration of lenacapavir with CYP450 3A4 inducers. Alternative treatments may be considered if an interaction is suspected.

References

  1. (2022) "Product Information. Sunlenca (lenacapavir)." Gilead Sciences

Switch to consumer interaction data

Drug and food interactions

Moderate

rufinamide food

Applies to: rufinamide

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of rufinamide. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of rufinamide. In healthy volunteers, administration of a single 400 mg dose of rufinamide with food resulted in an approximately 56% increase in mean peak plasma concentration (Cmax) and a 34% increase in systemic exposure (AUC) compared to administration during a fasting state.

MANAGEMENT: To ensure maximal oral absorption, it is preferable to administer rufinamide with food. Patients receiving rufinamide should be advised to avoid consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how rufinamide affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. (2008) "Product Information. Banzel (rufinamide)." Eisai Inc

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.